Logo image of RADX

RADIOPHARM THERANOSTICS LTD (RADX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RADX - ADR

4.45 USD
+0.06 (+1.37%)
Last: 12/9/2025, 1:13:03 PM
Fundamental Rating

3

RADX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of RADX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RADX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RADX has reported negative net income.
RADX had a negative operating cash flow in the past year.
In the past 5 years RADX always reported negative net income.
RADX had a negative operating cash flow in each of the past 5 years.
RADX Yearly Net Income VS EBIT VS OCF VS FCFRADX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

RADX's Return On Assets of -44.34% is in line compared to the rest of the industry. RADX outperforms 55.74% of its industry peers.
RADX has a Return On Equity (-85.60%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -44.34%
ROE -85.6%
ROIC N/A
ROA(3y)-52.36%
ROA(5y)-329.25%
ROE(3y)-111.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RADX Yearly ROA, ROE, ROICRADX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

RADX has a better Gross Margin (1.08%) than 71.94% of its industry peers.
RADX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RADX Yearly Profit, Operating, Gross MarginsRADX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

RADX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RADX has been increased compared to 1 year ago.
RADX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RADX Yearly Shares OutstandingRADX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 2M 4M 6M
RADX Yearly Total Debt VS Total AssetsRADX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -2.31, we must say that RADX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RADX (-2.31) is comparable to the rest of the industry.
There is no outstanding debt for RADX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.31
ROIC/WACCN/A
WACC8.87%
RADX Yearly LT Debt VS Equity VS FCFRADX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.67 indicates that RADX has no problem at all paying its short term obligations.
The Current ratio of RADX (2.67) is worse than 69.49% of its industry peers.
RADX has a Quick Ratio of 2.67. This indicates that RADX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.67, RADX is doing worse than 67.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.67
RADX Yearly Current Assets VS Current LiabilitesRADX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.80% over the past year.
The Revenue has grown by 1114.41% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.74%
Revenue 1Y (TTM)1114.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%651.94%

3.2 Future

Based on estimates for the next years, RADX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.83% on average per year.
Based on estimates for the next years, RADX will show a very strong growth in Revenue. The Revenue will grow by 109.54% on average per year.
EPS Next Y-12.82%
EPS Next 2Y0%
EPS Next 3Y-0.85%
EPS Next 5Y24.83%
Revenue Next Year-100%
Revenue Next 2Y30.21%
Revenue Next 3Y153.83%
Revenue Next 5Y109.54%

3.3 Evolution

RADX Yearly Revenue VS EstimatesRADX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RADX Yearly EPS VS EstimatesRADX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RADX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RADX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RADX Price Earnings VS Forward Price EarningsRADX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RADX Per share dataRADX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y-0.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RADX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RADIOPHARM THERANOSTICS LTD

NASDAQ:RADX (12/9/2025, 1:13:03 PM)

4.45

+0.06 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-25 2025-09-25/amc
Earnings (Next)N/A N/A
Inst Owners15.47%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap34.62M
Revenue(TTM)3.63M
Net Income(TTM)-38.34M
Analysts80
Price Target4.79 (7.64%)
Short Float %0.63%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.89%
PT rev (3m)-30.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-71.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.35
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.72
EYN/A
EPS(NY)-4.61
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.13
OCFYN/A
SpS0.31
BVpS3.82
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.34%
ROE -85.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.08%
FCFM N/A
ROA(3y)-52.36%
ROA(5y)-329.25%
ROE(3y)-111.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.67
Altman-Z -2.31
F-Score6
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.74%
EPS Next Y-12.82%
EPS Next 2Y0%
EPS Next 3Y-0.85%
EPS Next 5Y24.83%
Revenue 1Y (TTM)1114.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%651.94%
Revenue Next Year-100%
Revenue Next 2Y30.21%
Revenue Next 3Y153.83%
Revenue Next 5Y109.54%
EBIT growth 1Y9.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.13%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.5%
OCF growth 3YN/A
OCF growth 5YN/A

RADIOPHARM THERANOSTICS LTD / RADX FAQ

Can you provide the ChartMill fundamental rating for RADIOPHARM THERANOSTICS LTD?

ChartMill assigns a fundamental rating of 3 / 10 to RADX.


Can you provide the valuation status for RADIOPHARM THERANOSTICS LTD?

ChartMill assigns a valuation rating of 0 / 10 to RADIOPHARM THERANOSTICS LTD (RADX). This can be considered as Overvalued.


Can you provide the profitability details for RADIOPHARM THERANOSTICS LTD?

RADIOPHARM THERANOSTICS LTD (RADX) has a profitability rating of 1 / 10.


Can you provide the financial health for RADX stock?

The financial health rating of RADIOPHARM THERANOSTICS LTD (RADX) is 6 / 10.


What is the earnings growth outlook for RADIOPHARM THERANOSTICS LTD?

The Earnings per Share (EPS) of RADIOPHARM THERANOSTICS LTD (RADX) is expected to decline by -12.82% in the next year.